BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7(3): 344-361 [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Otaki Y, Ishida MD, Saito Y, Oyama Y, Oiso G, Moriyama M. Analysis of Closed Claims in the Clinical Management of Rheumatoid Arthritis in Japan. Chin Med J (Engl) 2017;130:1454-8. [PMID: 28584209 DOI: 10.4103/0366-6999.207479] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne) 2021;8:651658. [PMID: 34646834 DOI: 10.3389/fmed.2021.651658] [Reference Citation Analysis]
3 Antwi S, Oduro-mensah D, Obiri DD, Osafo N, Antwi AO, Ansah HO, Ocloo A, Okine LKN. Hydro-ethanol extract of Holarrhena floribunda stem bark exhibits anti-anaphylactic and anti-oedematogenic effects in murine models of acute inflammation. BMC Complement Med Ther 2022;22. [DOI: 10.1186/s12906-022-03565-6] [Reference Citation Analysis]
4 Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781-91. [PMID: 30198355 DOI: 10.1080/14787210.2018.1521270] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
5 Pisaturo M, Di Caprio G, Calò F, Portunato F, Martini S, Coppola N. Management of HBV reactivation in non-oncological patients. Expert Rev Anti Infect Ther 2018;16:611-24. [PMID: 30058401 DOI: 10.1080/14787210.2018.1505501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Kanda T, Yasui S, Nakamura M, Arai M, Sasaki R, Haga Y, Wu S, Nakamoto S, Okamoto H, Yokosuka O. Recent Trend of Hepatitis E Virus Infection in Chiba Area, Japan: 3 of 5 Cases with Rheumatoid Arthritis. Case Rep Gastroenterol 2015;9:317-26. [PMID: 26600768 DOI: 10.1159/000441387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Ostrov BE, Amsterdam D. Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases. Immunol Invest 2021;50:833-56. [PMID: 33941025 DOI: 10.1080/08820139.2021.1900863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Park YK, Park ES, Kim DH, Ahn SH, Park SH, Lee AR, Park S, Kang HS, Lee JH, Kim JM. Cleaved c-FLIP mediates the antiviral effect of TNF-α against hepatitis B virus by dysregulating hepatocyte nuclear factors. J Hepatol. 2016;64:268-277. [PMID: 26409214 DOI: 10.1016/j.jhep.2015.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
9 Becker I, Horneff G. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry. Arthritis Care & Research 2017;69:552-60. [DOI: 10.1002/acr.22961] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
10 Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics 2018;12:1-9. [PMID: 29391775 DOI: 10.2147/BTT.S148606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Alameel T, Al Sulais E. Risk of HBV Reactivation Among IBD patients With Occult Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2021;19:621-2. [PMID: 33248086 DOI: 10.1016/j.cgh.2020.04.089] [Reference Citation Analysis]
12 Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6. [PMID: 32098857 DOI: 10.1136/rmdopen-2019-001095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
13 Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038. [PMID: 27156434 DOI: 10.1016/s0140-6736(16)30173-8] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 663] [Article Influence: 231.2] [Reference Citation Analysis]
14 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31:1853-1859. [PMID: 28146345 DOI: 10.1111/jdv.14146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
16 Thalhammer F. Biologika und Infektionen: Therapeutischen Erfolg und Nebenwirkungen abwägen. rheuma plus 2016;15:42-9. [DOI: 10.1007/s12688-016-0066-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Husni ME. Comorbidities in Psoriatic Arthritis. Rheum Dis Clin North Am 2015;41:677-98. [PMID: 26476226 DOI: 10.1016/j.rdc.2015.07.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 54] [Article Influence: 11.1] [Reference Citation Analysis]
19 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
20 Almogairen SM. Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice. BMC Pharmacol Toxicol 2019;20:26. [PMID: 31064410 DOI: 10.1186/s40360-019-0303-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
21 Solay AH, Acar A, Eser F, Kuşcu F, Tütüncü EE, Kul G, Şentürk GÇ, Gürbüz Y. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turk J Gastroenterol 2018;29:561-5. [PMID: 30260778 DOI: 10.5152/tjg.2018.18032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
22 Caporali R, Crepaldi G, Codullo V, Benaglio F, Monti S, Todoerti M, Montecucco C. 20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology 2018;57:vii5-vii10. [DOI: 10.1093/rheumatology/key059] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
23 Saougou IG, Markatseli TE, Voulgari PV, Drosos AA. Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis. Curr Rheumatol Rev 2021;17:41-57. [PMID: 32942977 DOI: 10.2174/1573403X16999200917151805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-puttini P, Galli M. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine 2017;84:525-30. [DOI: 10.1016/j.jbspin.2017.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
25 Davignon JL, Rauwel B, Degboé Y, Constantin A, Boyer JF, Kruglov A, Cantagrel A. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review. Arthritis Res Ther 2018;20:229. [PMID: 30314507 DOI: 10.1186/s13075-018-1725-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
26 Gasperi C, Stüve O, Hemmer B. B cell-directed therapies in multiple sclerosis. Neurodegenerative Disease Management 2016;6:37-47. [DOI: 10.2217/nmt.15.67] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
27 Cobb BR, Valsamakis A. Chronic Hepatitis B, C, and D. Microbiol Spectr 2016;4. [PMID: 27726758 DOI: 10.1128/microbiolspec.DMIH2-0025-2015] [Reference Citation Analysis]
28 Md Yusof MY, Vital EM, Buch MH. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. Curr Rheumatol Rep 2015;17:65. [PMID: 26290110 DOI: 10.1007/s11926-015-0539-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
29 Padovan M, Filippini M, Tincani A, Lanciano E, Bruschi E, Epis O, Garau P, Mathieu A, Celletti E, Giani L, Tomietto P, Atzeni F, Sarzi Puttini P, Zuliani F, De Vita S, Trotta F, Grilli A, Puoti M, Govoni M. Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. Arthritis Care Res (Hoboken) 2016;68:738-43. [PMID: 26555747 DOI: 10.1002/acr.22786] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
30 Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol 2016;28:330-6. [PMID: 26986246 DOI: 10.1097/BOR.0000000000000281] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Annecca R, Pontecorvo S, Altieri M, Russo G, Svicher V, Mastroianni CM, Vullo V. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect Dis 2019;6:ofy356. [PMID: 30697576 DOI: 10.1093/ofid/ofy356] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
32 Moretto F, Catherine FX, Esteve C, Blot M, Piroth L. Isolated Anti-HBc: Significance and Management. J Clin Med. 2020;9. [PMID: 31940817 DOI: 10.3390/jcm9010202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zakaryan A, Ginosyan K. Perioperative Management of Patients With Ankylosing Spondylitis Undergoing Spine Surgery. Front Pharmacol 2020;11:1017. [PMID: 32742263 DOI: 10.3389/fphar.2020.01017] [Reference Citation Analysis]
34 Kridin M, Zloto O, Kridin K, Cohen AD, Mann O, Weinstein O. The association of uveitis with hepatitis B and hepatitis C viruses: a large-scale population-based study. Eye (Lond) 2022. [PMID: 35352013 DOI: 10.1038/s41433-022-02037-y] [Reference Citation Analysis]
35 Dropulic LK, Lederman HM. Overview of Infections in the Immunocompromised Host. Microbiol Spectr 2016;4. [PMID: 27726779 DOI: 10.1128/microbiolspec.DMIH2-0026-2016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
36 Tien YC, Yen HH, Li CF, Liu MP, Hsue YT, Hung MH, Chiu YM. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Res Ther 2018;20:246. [PMID: 30382902 DOI: 10.1186/s13075-018-1748-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
37 Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo SF, Mu R, Nash P, Ng CT, Suryana B, Wijaya LK, Yeap SS. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 2019;22:357-75. [PMID: 30809944 DOI: 10.1111/1756-185X.13513] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 15.3] [Reference Citation Analysis]
38 Papeix C, Donze C, Lebrun-Frénay C; French Group for Recommendations in Multiple Sclerosis (France4MS), the Société Francophone de la Sclérose En Plaques (SFSEP)., Co-Chairs., Group of evaluators Coordinators., Readers., Cotator., Expert readers (voters). Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris) 2021:S0035-3787(21)00602-0. [PMID: 34303537 DOI: 10.1016/j.neurol.2021.04.011] [Reference Citation Analysis]
39 Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs 2021;35:861-80. [PMID: 34319570 DOI: 10.1007/s40263-021-00842-9] [Reference Citation Analysis]
40 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. Clin Liver Dis 2019;23:521-34. [PMID: 31266625 DOI: 10.1016/j.cld.2019.04.012] [Reference Citation Analysis]
41 Friedman MA, Winthrop KL. Vaccines and Disease-Modifying Antirheumatic Drugs. Rheumatic Disease Clinics of North America 2017;43:1-13. [DOI: 10.1016/j.rdc.2016.09.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
42 Piaserico S, Conti A, Coati I, Galdo G, Bernabucci V, Zanca A, Drabeni M, Masutti F, Musumeci ML, Alberti A, Russo FP. Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. G Ital Dermatol Venereol 2019;154. [DOI: 10.23736/s0392-0488.17.05487-6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Makalish TP, Golovkin IO, Oberemok VV, Laikova KV, Temirova ZZ, Serdyukova OA, Novikov IA, Rosovskyi RA, Gordienko AI, Zyablitskaya EY, Gafarova EA, Yurchenko KA, Fomochkina II, Kubyshkin AV. Anti-Rheumatic Effect of Antisense Oligonucleotide Cytos-11 Targeting TNF-α Expression. Int J Mol Sci 2021;22:1022. [PMID: 33498456 DOI: 10.3390/ijms22031022] [Reference Citation Analysis]
44 Chaigne B, Watier H. Theranostic of biopharmaceuticals. Pharmacol Ther 2017;175:67-74. [PMID: 28223229 DOI: 10.1016/j.pharmthera.2017.02.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]